Physician profile
Stephen E Lookadoo
NPI 1538104005
$578.65
in general payments reported to CMS, 2019-2025
15 companies · $20.67 in 2025
The $20.67 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $14.83 · 2021: $171 · 2022: $139 · 2023: $22.49 · 2024: $25.16 · 2025: $20.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $86.77 | 2019-2022 | |
| Corium, LLC | $78.95 | 2021-2023 | Azstarys |
| Tris Pharma INC | $70.41 | 2019-2022 | |
| Genentech USA, INC. | $57.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.60 | 2019-2021 | |
| Cranial Technologies, INC | $39.70 | 2022-2025 | Doc Band |
| Pfizer INC. | $37.27 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $26.12 | 2021-2022 | |
| Daiichi Sankyo INC. | $23.81 | 2022 | |
| Hikma Pharmaceuticals USA | $22.36 | 2021 | |
| Eyevance Pharmaceuticals LLC | $22.36 | 2021 | |
| Shire North American Group INC | $19.22 | 2019 | |
| Adlon Therapeutics L.P. | $15.13 | 2021 | |
| Novo Nordisk INC | $15.10 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lookadoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.